Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study
Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Simona Frezzini, Germana Tognon, Grazia Artioli, Angiolo Gadducci, Rossella Lauria, Annamaria Ferrero, Saverio Cinieri, Andrea De Censi, Enrico Breda, Paolo Scollo, Ugo De Giorgi, Andrea Alberto Lissoni, Dionyssios Katsaros, Domenica Lorusso, Vanda Salutari, Sabrina Chiara Cecere, Eleonora Zaccarelli, Margherita Nardin, Giorgio Bogani, Mariagrazia Distefano, Stefano Greggi, Maria Carmela Piccirillo, Roldano Fossati, Gaia Giannone, Laura Arenare, Ciro Gallo, Francesco Perrone, Sandro Pignata
Topics & Concepts
MedicineBevacizumabCarboplatinInternal medicineHazard ratioOvarian cancerOncologyClinical endpointPaclitaxelPopulationProgression-free survivalCancerClinical trialChemotherapySurgeryConfidence intervalEnvironmental healthCisplatinOvarian cancer diagnosis and treatmentAngiogenesis and VEGF in CancerIntraperitoneal and Appendiceal Malignancies